TME PHARMA ANNOUNCES THE INITIATION OF THE LISTING OF PREFERENTIAL SUBSCRIPTION RIGHTS FOR FULLY GUARANTEED €2.7 MILLION CAPITAL INCREASE

- Guaranteed portion of the transaction will extend cash runway past
regulatory milestones in Q1-2024
- The financial visibility will allow TME Pharma to file and receive
feedback from FDA on its IND and applications to expedited regulatory
review pathways
- Current shareholders to receive preferential rights to participate in
capital raise issuing shares with warrants attached
- Buyback of nearly half of outstanding convertible debt and lock-up of
the remainder until April 1, 2024
- New warrants issued with potential to raise an additional €2.2 million
and extend cash runway into September 2024 if fully exercised

Berlin, Germany, November 28, 2023, 08.00 a.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced on November 24, 2023, the launch of a 100% guaranteed capital increase through issuance of new shares for €2.7 million gross proceeds with associated warrants potentially raising up to €2.2 million of additional gross proceeds in order to secure financing to reach key regulatory milestones in 2024. The guaranteed amount is secured by a group of Dutch investors.

More information

 

Back